Our Impact

Eric Pierce MD PhD and Jason Comander MD PhD and Rachel Huckfeldt MD PhD in an eye exam room all in discussion

Changing lives one rare disease at time

Odylia utilizes a unique, nonprofit business model to accelerate the development of gene therapies for people with rare disease, changing the way treatments are brought from the lab to the clinic. Our ultimate goal is to bring life changing treatments to people with genetic disease regardless of prevalence or commercial interest

Odylia challenges the traditional approach to drug development through the following areas of focus:

Lower cost of development

Lower licensing fees to decrease development costs and ensure continued commitment to program success

Increase speed of development

Challenge traditional approaches through regulatory engagement

Streamline development through strategic partnerships and a platform approach to drug development

Enable the entire ecosystem

Provide expertise through in-house Brydge Solutions and leveraging the Odylia Board

Enable the entire ecosystem through Initiatives that impact the broader field

Questions? We’re here to help!